Introduction
============

Gastric cancer remains one of the most common malignancies all over the world, particularly in Asia [@B1]-[@B3]. Most patients are diagnosed with advanced stages on account of unspecific symptoms [@B4], [@B5]. There are still no curable treatments but only approved treatments like chemotherapy and immunotherapy for metastatic gastric cancer patients currently [@B6]. Though targeted drugs can prolong the survival time of metastatic patients, the median is approximately 11-16 months [@B7]. With the development of therapeutic approaches, metastatic gastric cancer patients have opportunities to survive better [@B8]. However, early death (survival time ≤3 months) of metastatic gastric cancer patients remains unsolved problems [@B8]. Therefore, it\'s necessary to identify risk factors of early death in gastric cancer patients. Such studies had been reported in colorectal cancer and ovarian cancer, but the researches in gastric cancer were rarely reported [@B9], [@B10].

This study aimed to recognize risk factors and establish a predictive nomogram for the early death of metastatic gastric cancer patients based on a large population cohort and a Chinese cohort.

Materials and Methods
=====================

Population
----------

The SEER database, supported by the National Cancer Institute, constituted approximately 27.8% of the US population. SEER\*Stat software (Version 8.3.6) was used to extract clinical information. We applied the primary site codes C16.0-C16.9 for gastric and the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) histologic codes 8140/3 (Adenocarcinoma, NOS), 8211/3 (Tubular adenocarcinoma), 8260/3 (Papillary adenocarcinoma), 8480/3 (Mucinous adenocarcinoma), 8490/3 (Signet ring cell carcinoma) for adenocarcinoma. The information for metastatic sites of the bone (SEER Combined Mets at DX-bone), brain (SEER Combined Mets at DX-brain), liver (SEER Combined Mets at DX-liver), and lung (SEER Combined Mets at DX-lung) were collected since 2010, thus metastatic gastric cancer patients diagnosed stage IV and from 2010 to 2015 were included. Patients of metastatic gastric cancer without histological confirmation, only one primary malignancy, survival months, race, marital status, grade, and cause of death were excluded. Surgery was not recommended in metastatic gastric cancer; therefore T stage and N stage without specific information were accepted. Demographic and clinical characteristics were withdrawn in the SEER database as follows: age, sex, race, marital status, primary site, histology, grade, bone metastases, brain metastases, liver metastases, lung metastases, T stage, N stage, surgery, radiation, chemotherapy, cause of death, survival months.

The clinical data for metastatic gastric cancer patients initially diagnosed at Cancer Center, Union Hospital between January 2011 and September 2018 were collected retrospectively. The last follow-up was in January 2019. The inclusion and exclusion criteria mentioned above for the SEER cohort were also applied to the Chinese cohort. Surgery was not observed in the Chinese cohort and marital status was not recorded as well. T stage and N stage were mainly based on CT or endoscopic ultrasonography. Besides, smoking and drinking history were recorded. Death less than 3 months since the first diagnosis was regarded as early death in patients with malignant tumors.

This retrospective study of the Chinese cohort was approved by the ethics committee of Tongji Medical College, Huazhong University of Science and Technology in accordance with the ethical standards prescribed by the Helsinki Declaration.

Nomogram Development and Statistical analysis
---------------------------------------------

Categorical data were described by the number and the percentage (N, %). Univariate and multivariate logistic regression models were utilized to identify variables that significantly associated with the early death of metastatic gastric cancer in the SEER sets. Then the predictive nomogram based on independent factors was constructed for the early death of metastatic gastric cancer by the SEER cohort. To evaluate the calibration and discrimination of the nomogram, an external independent Chinese patient validation cohort was used. For calibration, the nomogram predicted probabilities were contrasted with the actual probabilities by bootstrapping with 1000 resamples. The receiver operating characteristic (ROC) curve was used to judge discrimination. The higher the area under the curve (AUC) was, the better the accuracy would be. The "DynNom" and "shiny" packages were used to construct a web-based probability calculator, which could dynamically predict the probability of early death.

All analyses were performed using the R software (version 3.6.2). A two-tailed *P* value less than 0.01 was considered statistically significant.

Results
=======

Demographic and clinical characteristics
----------------------------------------

There were 4575 patients in the SEER database and 220 patients in our cancer center enrolled in this study. The demographic and clinical characteristics of metastatic gastric cancer were listed in Table [1](#T1){ref-type="table"}.

For the SEER cohort, most patients (82.4%) were between 40 to 79 years old. 65.3% of the patients are male and 61.3% are married. The main primary sites were gastric antrum and cardiac. The most common metastatic sites were liver, accounting for approximately 43.2% of liver metastases. Only 10.3% of patients performed surgery and 19.6% of patients performed radiation. There were nearly 67.6% of patients that received chemotherapy. The majority of metastatic gastric cancer patients died of the primary disease, while few of them died of other causes such as heart disease, cerebrovascular disease, septicemia, and so on.

In the Chinese cohort, the majority of patients (91.9%) were between 40 to 79 years old. The proportion of male patients was nearly equal to female patients. Approximately 20.9% and 20.0% of patients had a smoking history and drinking history, respectively. Metastatic gastric cancer patients constituted 32.3% of the liver metastases. Most patients (72.3%) received chemotherapy.

Identifying independent factors for early death
-----------------------------------------------

By applying univariate and multivariate logistic regression in the SEER cohort, the risk variables for the early death of metastatic gastric cancer were analyzed (Table [2](#T2){ref-type="table"}). Univariate logistic models showed that age, marital status, primary site, grade, metastases of bone, brain metastases, metastases of liver, lung metastases, T stage, N stage, surgery, radiation, and chemotherapy were associated with early death. Multivariate analyses proved eight independent risk factors including race, grade, surgery, chemotherapy, and metastases of bone, brain, liver, lung, which were significantly related to the early death of metastatic gastric cancer.

Nomogram construction
---------------------

The predictive nomogram relying on identified risk factors from multivariate logistic regression models in the SEER cohort was constructed in Figure [1](#F1){ref-type="fig"}. By calculating every point of variables, the total number of points could be associated with the probability of early death of metastatic gastric cancer.

Nomogram validation
-------------------

The predictive nomogram was validated both in the SEER cohort and the Chinese cohort. For the Chinese cohort, nomogram predicted probabilities of early death were computed according to the nomogram based on the SEER cohort. The calibration plots performed well both in the training and validation cohort (Figure [2](#F2){ref-type="fig"}C-D). Besides, applicable AUC was shown in both sets (Figure [2](#F2){ref-type="fig"}A-B).

Web-based probability calculator
--------------------------------

According to the above results, a dynamic web-based probability calculator (https:/wandertheworld.shinyapps.io/DynNomapp/) was constructed to predict the early death of metastatic gastric cancer patients on the basis of the previous nomogram (Figure [3](#F3){ref-type="fig"}A). It\'s very convenient to individually predict the early death probability of patients based on their clinical characteristics. For instance, the early death probability of metastatic gastric cancer was approximately 27.9% (95% *CI*: 24.0-32.1%) for white patients with a poorly or differentiated grade, bone metastasis, chemotherapy, and without brain metastasis, liver metastasis, lung metastasis, surgery (Figure [3](#F3){ref-type="fig"}B).

Discussion
==========

The incidence and morbidity of gastric cancer remained high worldwide [@B11]. Thanks to the development of a number of treatments including targeted drugs, immunotherapy, and radiation, the median survival time had been prolonged all the time [@B12]-[@B16]. However, one-third and one-fifth of early death which was defined as death came up within 3 months occurred in the SEER cohort and the Chinese cohort of this study, respectively. Researchers concentrated deeply on associated independent variables of overall survival, cancer-specific survival, and noncancer-specific survival in gastric cancer [@B17]-[@B19]. And nomograms had been widely developed and used for predicting long-term survival of cancers [@B20]-[@B24]. To the best of our knowledge, this was the first study to identify the associated risk factors and structure an available nomogram for recognizing the early death of metastatic gastric cancer patients.

For the SEER cohort, multivariate analyses identified eight independent risk factors, including race, grade, surgery, chemotherapy, and metastases of bone, brain, liver, lung. Some previous studies had reported that grade, surgery, chemotherapy, and distant metastasis were significantly related to overall survival [@B25], [@B26]. This study firstly confirmed that these risk factors were related to early death. Since some studies showed that metastatic gastric cancer patients performing surgical resection had a relatively poor prognosis, the surgery for metastatic gastric cancer patients remained controversial [@B27]. Furthermore, for those stage IV gastric cancer patients with synchronous liver metastasis, surgery had been reconsidered with the improvement of longer overall survival time [@B28], [@B29].

There were apparent differences between the SEER cohort and the Chinese cohort. A lot of factors might result in the differences, including incidence, insurance, economic conditions, treatment strategy, religious beliefs, and so on.

A convenient nomogram containing identified independent factors was constructed for predicting early death of metastatic gastric cancer patients. Once they were distinguished, closer attention and better therapeutic strategies such as clinical trials might be given by oncologists.

There were several limitations to this study. First, risk factors associated with early death, including peritoneal metastasis, numbers of metastatic sites, performance status, and background diseases were absent. Second, the excluded missing data might result in selection bias. Third, though a Chinese cohort was used to validate the nomogram, a large prospective study was requisite.

All in all, a comprehensive nomogram integrating identified risk factors and a web-based probability calculator based on the nomogram were constructed to distinguish the early death of metastatic gastric cancer patients. The nomogram might help oncologists to make better therapeutic strategies such as clinical trials, and hospice management.
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###### 

Demographic and clinical characteristics in the SEER database and Chinese cohort

  Characteristic               SEER cohort   Chinese cohort                                                                                                
  ---------------------------- ------------- ---------------- ------------ ------------- ------------ ------------- ------------ ------------ ------------ ------------
  **Age (years)**                                                                                                                                          
  \<40                         261 (5.7)     72 (4.4)         56 (6.5)     79 (7.3)      54 (5.5)     17 (7.7)      5 (11.1)     1 (2.1)      3 (4.3)      8 (14.0)
  40-59                        1581 (34.6)   463 (28.1)       313 (36.3)   411 (38.2)    394 (39.8)   100 (45.5)    17 (37.8)    27 (56.3)    35 (50.0)    21 (36.8)
  60-79                        2185 (47.8)   799 (48.5)       387 (44.8)   517 (48.1)    482 (48.7)   102 (46.4)    23 (51.1)    20 (41.7)    31 (44.3)    28 (49.1)
  80+                          548 (12.0)    313 (19.0)       107 (12.4)   68 (6.3)      60 (6.1)     1 (0.5)       0 (0.0)      0 (0.0)      1 (1.4)      0 (0.0)
  **Sex**                                                                                                                                                  
  Male                         2986 (65.3)   1070 (65.0)      560 (64.9)   700 (65.1)    656 (66.3)   113 (51.4)    22 (48.9)    20 (41.7)    38 (54.3)    33 (57.9)
  Female                       1589 (34.7)   577 (35.0)       303 (35.1)   375 (34.9)    334 (33.7)   107 (48.6)    23 (51.1)    28 (58.3)    32 (45.7)    24 (42.1)
  **Race**                                                                                                                                                 
  White                        3384 (74.0)   1229 (74.6)      622 (72.1)   807 (75.1)    726 (73.3)   0 (0.0)       0 (0.0)      0 (0.0)      0 (0.0)      0 (0.0)
  Black                        558 (12.2)    214 (13.0)       98 (11.4)    122 (11.3)    124 (12.5)   0 (0.0)       0 (0.0)      0 (0.0)      0 (0.0)      0 (0.0)
  Others                       633 (13.8)    204 (12.4)       143 (16.6)   146 (13.6)    140 (14.1)   220 (100.0)   45 (100.0)   48 (100.0)   70 (100.0)   57 (100.0)
  **Marital status**                                                                                                                                       
  Married                      2806 (61.3)   896 (54.4)       538 (62.3)   715 (66.5)    657 (66.4)   NA            NA           NA           NA           NA
  Separated/Divorced           489 (10.7)    188 (11.4)       88 (10.2)    108 (10.0)    105 (10.6)   NA            NA           NA           NA           NA
  Widowed                      472 (10.3)    242 (14.7)       89 (10.3)    76 (7.1)      65 (6.6)     NA            NA           NA           NA           NA
  Single                       808 (17.7)    321 (19.5)       148 (17.1)   176 (16.4)    163 (16.5)   NA            NA           NA           NA           NA
  **Smoking history**                                                                                                                                      
  Yes                          NA            NA               NA           NA            NA           46 (20.9)     11 (24.4)    10 (20.8)    13 (18.6)    12 (21.1)
  No                           NA            NA               NA           NA            NA           174 (79.1)    34 (75.6)    38 (79.2)    57 (81.4)    45 (78.9)
  **Drinking history**                                                                                                                                     
  Yes                          NA            NA               NA           NA            NA           44 (20.0)     8 (17.8)     10 (20.8)    16 (22.9)    10 (17.5)
  No                           NA            NA               NA           NA            NA           176 (80.0)    37 (82.2)    38 (79.2)    54 (77.1)    47 (82.5)
  **Primary site**                                                                                                                                         
  Cardiac/fundus               1907 (41.7)   626 (38.0)       353 (40.9)   469 (43.6)    459 (46.4)   52 (23.6)     6 (13.3)     10 (20.8)    23 (32.9)    13 (22.8)
  Body                         451 (9.9)     158 (9.6)        98 (11.4)    110 (10.2)    85 (8.6)     55 (25.0)     17 (37.8)    12 (25.0)    15 (21.4)    11 (19.3)
  Antrum/pylorus               690 (15.1)    269 (16.3)       113 (13.1)   156 (14.5)    154 (15.6)   60 (27.3)     14 (31.1)    8 (16.7)     17 (24.3)    21 (36.8)
  Lesser/greater curvature     846 (18.5)    140 (8.5)        79 (9.2)     100 (9.3)     82 (8.3)     2 (0.9)       1 (2.2)      1 (2.1)      0 (0.0)      0 (0.0)
  Other                        681 (14.9)    454 (27.6)       220 (25.5)   243 (22.6)    210 (21.1)   51 (23.2)     7 (15.6)     17 (35.4)    15 (21.4)    12 (21.1)
  **Histology**                                                                                                                                            
  Adenocarcinoma               3358 (73.4)   1232 (74.8)      626 (72.5)   767 (71.3)    733 (74.0)   182 (82.7)    37 (82.2)    41 (85.4)    59 (84.3)    45 (78.9)
  Signet ring cell carcinoma   1217 (26.6)   415 (25.2)       237 (27.5)   308 (28.7)    257 (26.0)   38 (17.3)     8 (17.8)     7 (14.6)     11 (15.7)    12 (21.1)
  **Grade**                                                                                                                                                
  Well/moderately              1101 (24.1)   344 (20.9)       194 (22.5)   276 (25.7)    287 (29.0)   182 (82.7)    37 (82.2)    41 (85.4)    59 (84.3)    45 (78.9)
  Poorly /undifferentiated     3474 (75.9)   1303 (79.1)      669 (77.5)   799 (74.3)    703 (71.0)   38 (17.3)     8 (17.8)     7 (14.6)     11 (15.7)    12 (21.1)
  **Bone metastases**                                                                                                                                      
  Yes                          607 (13.3)    254 (15.4)       122 (14.1)   146 (13.6)    85 (8.6)     24 (10.9)     4 (8.9)      8 (16.7)     6 (8.6)      6 (10.5)
  No/unknown                   3968 (86.7)   1393 (84.6)      741 (85.9)   929 (86.4)    905 (91.4)   196 (89.1)    41 (91.1)    40 (83.3)    64 (91.4)    51 (89.5)
  **Brain metastases**                                                                                                                                     
  Yes                          95 (2.1)      55 (3.3)         17 (2.0)     9 (0.8)       14 (1.4)     2 (0.9)       0 (0.0)      1 (2.1)      1 (1.4)      0 (0.0)
  No/unknown                   4480 (97.9)   1592 (96.7)      846 (98.0)   1066 (99.2)   976 (98.6)   218 (99.1)    45 (100.0)   47 (97.9)    69 (98.6)    57 (100.0)
  **Liver metastases**                                                                                                                                     
  Yes                          1975 (43.2)   764 (46.4)       366 (42.4)   453 (42.1)    392 (39.6)   71 (32.3)     18 (40.0)    15 (31.3)    20 (28.6)    18 (31.6)
  No/unknown                   2600 (56.8)   883 (53.6)       497 (57.6)   622 (57.9)    598 (60.4)   149 (67.7)    27 (60.0)    33 (68.8)    50 (71.4)    39 (68.4)
  **Lung metastases**                                                                                                                                      
  Yes                          656 (14.3)    275 (16.7)       127 (14.7)   145 (13.5)    109 (11.0)   14 (6.4)      1 (2.2)      4 (8.3)      5 (7.1)      4 (7.0)
  No/unknown                   3919 (85.7)   1372 (83.3)      736 (85.3)   930 (86.5)    881 (89.0)   206 (93.6)    44 (97.8)    44 (81.7)    65 (92.9)    53 (93.0)
  **T stage**                                                                                                                                              
  T1                           822 (18.0)    302 (18.3)       161 (18.7)   190 (17.7)    169 (17.1)   1 (0.5)       1 (2.2)      0 (0.0)      0 (0.0)      0 (0.0)
  T2                           200 (4.4)     51 (3.1)         35 (4.1)     45 (4.2)      69 (7.0)     3 (1.4)       0 (0.0)      1 (2.1)      0 (0.0)      2 (3.5)
  T3                           742 (16.2)    205 (12.4)       141 (16.3)   191 (17.8)    205 (20.7)   24 (10.9)     4 (8.9)      2 (4.2)      10 (14.3)    8 (14.0)
  T4                           1004 (21.9)   354 (21.5)       192 (22.2)   249 (23.2)    209 (21.1)   49 (22.3)     5 (11.1)     6 (12.5)     13 (18.6)    25 (43.9)
  Unknown                      1807 (39.5)   735 (44.6)       334 (38.7)   400 (37.2)    338 (34.1)   143 (65.0)    35 (77.8)    39 (81.3)    47 (67.1)    22 (38.6)
  **N stage**                                                                                                                                              
  N0                           1542 (33.7)   613 (37.2)       294 (34.1)   321 (29.9)    314 (31.7)   4 (1.8)       1 (2.2)      1 (2.1)      0 (0.0)      2 (3.5)
  N1                           1708 (37.3)   545 (33.1)       333 (38.6)   449 (41.8)    381 (38.5)   5 (2.3)       0 (0.0)      0 (0.0)      2 (2.9)      3 (5.3)
  N2                           301 (6.6)     72 (4.4)         51 (5.9)     75 (7.0)      103 (10.4)   23 (10.5)     3 (6.7)      0 (0.0)      12 (17.1)    8 (14.0)
  N3                           305 (6.7)     79 (4.8)         60 (7.0)     79 (7.3)      87 (8.8)     32 (14.5)     2 (4.4)      7 (14.6)     6 (8.6)      17 (29.8)
  Unknown                      719 (15.7)    338 (20.5)       125 (14.5)   151 (14.0)    105 (10.6)   156 (70.9)    39 (86.7)    40 (83.3)    50 (71.4)    27 (47.4)
  **Surgery**                                                                                                                                              
  Yes                          470 (10.3)    99 (6.0)         68 (7.9)     125 (11.6)    178 (18.0)   0 (0.0)       0 (0.0)      0 (0.0)      0 (0.0)      0 (0.0)
  No/unknown                   4105 (89.7)   1548 (94.0)      795 (92.1)   950 (88.4)    812 (82.0)   220 (100.0)   45 (100.0)   48 (100.0)   70 (100.0)   57 (100.0)
  **Radiation**                                                                                                                                            
  Yes                          896 (19.6)    289 (17.5)       167 (19.4)   226 (21.0)    214 (21.6)   14 (6.4)      0 (0.0)      1 (2.1)      7 (10.0)     6 (10.5)
  No/unknown                   3679 (80.4)   1358 (82.5)      696 (80.6)   849 (79.0)    776 (78.4)   206 (93.6)    45 (100.0)   47 (97.9)    63 (90.0)    51 (89.5)
  **Chemotherapy**                                                                                                                                         
  Yes                          3096 (67.6)   639 (38.8)       640 (74.2)   923 (85.9)    892 (90.1)   159 (72.3)    15 (33.3)    41 (85.4)    56 (80.0)    47 (82.5)
  No/unknown                   1481 (32.4)   1008 (61.2)      223 (25.8)   152 (14.1)    98 (9.9)     61 (27.7)     30 (66.7)    7 (14.6)     14 (20.0)    10 (17.5)
  **Cause of death**                                                                                                                                       
  Gastric cancer               4434 (96.9)   1588 (96.4)      842 (97.6)   1044 (97.1)   960 (97.0)   NA            NA           NA           NA           NA
  Other causes                 141 (3.1)     59 (3.6)         21 (2.4)     31 (2.9)      30 (3.0)     NA            NA           NA           NA           NA

Abbreviations: not available, NA.

###### 

Univariate and multivariate logistic regression for analyzing the risk factors for early death in the SEER database

  Variables                    Univariate   Multivariate                                       
  ---------------------------- ------------ -------------- ------------- ------- ------------- -------------
  **Age (years)**                                                                              
  \<40                         Ref                                       Ref                   
  40-59                        1.087        0.815-1.463    0.575         0.836   0.603-1.168   0.286
  60-79                        1.513        1.143-2.023    **0.004**     1.106   0.799-1.545   0.548
  80+                          3.496        2.549-4.836    **\<0.001**   1.458   0.993-2.152   0.056
  **Sex**                                                                                      
  Male                         Ref                                       Ref                   
  Female                       1.021        0.899-1.159    0.748         0.828   0.704-0.973   0.022
  **Race**                                                                                     
  White                        Ref                                       Ref                   
  Black                        1.091        0.906-1.311    0.356         0.910   0.727-1.137   0.410
  Other                        0.834        0.695-0.998    0.049         0.706   0.569-0.874   **0.001**
  **Marital status**                                                                           
  Married                      Ref                                       Ref                   
  Separated/Divorced           0.049        1.090-1.623    **0.005**     1.305   1.034-1.642   0.024
  Widowed                      2.243        1.842-2.732    **\<0.001**   1.241   0.963-1.598   0.094
  Single                       1.405        1.195-1.651    **\<0.001**   1.273   1.047-1.547   0.015
  **Primary site**                                                                             
  Cardiac/fundus               Ref                                       Ref                   
  Body                         1.103        0.888-1.367    0.371         1.201   0.921-1.561   0.174
  Antrum/pylorus               1.308        1.091-1.565    **0.004**     1.305   1.036-1.644   0.023
  Lesser& greater curvature    1.184        0.999-1.401    0.051         1.314   1.064-1.620   0.011
  Other                        1.464        1.222-1.752    **\<0.001**   1.148   0.919-1.435   0.223
  **Histology**                                                                                
  Adenocarcinoma               Ref                                       Ref                   
  Signet ring cell carcinoma   0.893        0.778-1.024    0.107         0.999   0.831-1.201   0.996
  **Grade**                                                                                    
  Well/moderately              Ref                                       Ref                   
  Poorly /undifferentiated     1.321        1.144-1.528    **\<0.001**   1.904   1.588-2.287   **\<0.001**
  **Bone metastases**                                                                          
  Yes                          Ref                                       Ref                   
  No/unknown                   0.752        0.632-0.895    **0.001**     0.64    0.521-0.786   **\<0.001**
  **Brain metastases**                                                                         
  Yes                          Ref                                       Ref                   
  No/unknown                   0.401        0.264-0.603    **\<0.001**   0.328   0.202-0.529   **\<0.001**
  **Liver metastases**                                                                         
  Yes                          Ref                                       Ref                   
  No/unknown                   0.815        0.722-0.921    **0.001**     0.798   0.682-0.934   **0.005**
  **Lung metastases**                                                                          
  Yes                          Ref                                       Ref                   
  No/unknown                   0.746        0.631-0.884    **0.001**     0.749   0.614-0.915   **0.004**
  **T stage**                                                                                  
  T1                           Ref                                       Ref                   
  T2                           0.589        0.413-0.830    **0.003**     0.591   0.391-0.883   0.011
  T3                           0.657        0.530-0.814    **\<0.001**   0.928   0.719-1.197   0.566
  T4                           0.938        0.774-1.136    0.512         1.121   0.887-1.418   0.341
  Unknown                      1.181        0.996-1.400    0.056         1.051   0.858-1.289   0.630
  **N stage**                                                                                  
  N0                           Ref                                       Ref                   
  N1                           0.710        0.615-0.820    **\<0.001**   0.821   0.692-0.973   0.023
  N2                           0.476        0.357-0.630    **\<0.001**   0.703   0.500-0.982   0.041
  N3                           0.530        0.400-0.695    **\<0.001**   0.783   0.553-1.102   0.164
  Unknown                      1.344        1.125-1.607    **0.001**     1.245   1.005-1.542   0.045
  **Surgery**                                                                                  
  Yes                          Ref                                       Ref                   
  No/unknown                   2.269        1.809-2.870    **\<0.001**   2.697   1.993-3.675   **\<0.001**
  **Radiation**                                                                                
  Yes                          Ref                                       Ref                   
  No/unknown                   1.229        1.053-1.437    **0.009**     0.985   0.815-1.193   0.879
  **Chemotherapy**                                                                             
  Yes                          Ref                                       Ref                   
  No/unknown                   8.187        7.125-9.422    **\<0.001**   8.53    7.308-9.978   **\<0.001**
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